

PCTWORLD INTELLECTUAL PROP.
International B

INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 9606530A1

(51) International Patent Classification 6 : A01N 37/02, 37/00	A1	(11) International Publication Number: WO 96/06530 (43) International Publication Date: 7 March 1996 (07.03.96)
<p>(21) International Application Number: PCT/US95/10141</p> <p>(22) International Filing Date: 17 August 1995 (17.08.95)</p> <p>(30) Priority Data: 08/297,863 30 August 1994 (30.08.94) US</p> <p>(71) Applicants: CORNELL RESEARCH FOUNDATION, INC. [US/US]; Suite 105, 20 Thornwood Drive, Ithaca, NY 14850 (US). NEW ENGLAND DEACONESS HOSPITAL CORP. [US/US]; 185 Pilgrim Road, Boston, MA 02215 (US).</p> <p>(72) Inventors: DANNENBERG, Andrew, J.; Apartment 14A, 7 Gracie Square, New York, NY 10028 (US). NANJL, Amin, A.; 38 Crestwood, Wellesley, MA 02181 (US).</p> <p>(74) Agent: SPECTOR, Eric, S.; Jones, Tullar & Cooper, P.C., P.O. Box 2266 Eads Station, Arlington, VA 22202 (US).</p>		<p>(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: METHOD OF TREATING INFLAMMATORY LIVER, PANCREATIC AND INTESTINAL DISORDERS</p> <p>(57) Abstract</p> <p>An enteral diet containing fat in an amount to provide from 20 to 50 % of total calories, said fat containing less than 15 % polyunsaturated fat (e.g., palm oil or medium chain triglycerides) is administered to mediate amelioration of the inflammation associated with the inflammatory liver, pancreatic and intestinal disorders, e.g., to promote healing of the liver in alcoholic hepatitis.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

METHOD OF TREATING INFLAMMATORY LIVER PANCREATIC AND INTESTINAL DISORDERS

This invention was made at least in part under National Institutes of Health grant number DK01992. The Government has certain rights in the invention.

Technical Field

This invention is directed at treating inflammation of the liver, pancreas and intestine. These include, for example, alcoholic hepatitis, viral hepatitis, pancreatitis, Crohn's disease and ulcerative colitis.

Background of the Invention

Alcohol-related liver disease is a significant problem throughout the world. Cirrhosis is a leading cause of death in American urban men between the ages of 25-64. In addition, women appear to be even more susceptible than men to alcohol-related morbidity and mortality. Hospitalization costs, disability, and loss of productivity related to alcoholic liver disease amount to billions of dollars of costs annually in the United States.

Alcoholic hepatitis is the term for a clinicopathologic syndrome resulting from excessive alcohol consumption characterized by an acute or subacute clinical presentation and a distinctive appearance on liver biopsy. Mild cases may resolve spontaneously after cessation of alcohol consumption. Hospitalized patients with severe alcoholic hepatitis, however, have a one month mortality between 29-52%. In addition to

the short-term mortality, the probability of alcohol-related hepatitis progressing to cirrhosis is estimated at 10-20%/yr. Long-term survival rates are influenced by continued alcohol consumption and nutritional factors, but return to normal liver function and architecture after an episode of alcoholic hepatitis are possible.

The high mortality rate for hospitalized alcoholic hepatitis patients is observed despite aggressive treatment of fluid and electrolyte disturbances, malnutrition, withdrawal symptoms, encephalopathy, gastrointestinal bleeding, and infection. Numerous trials for alcohol-related liver disease have been undertaken including treatment with anabolic steroids, colchicine, propylthiouracil, nutritional support, and insulin/glucagon. None of these treatments has been unequivocally associated with decreased mortality during the acute illness or diminished progression of alcoholic hepatitis to cirrhosis.

Nor is the scenario for other inflammatory liver, pancreatic and intestinal disorders much more positive.

There is no recognized treatment for chronic viral hepatitis other than interferon administration and interferon administration has proven effective only in a minority of patients and may cause significant side effects. Chronic viral hepatitis may progress to cirrhosis and/or liver cancer.

There is no known treatment for decreasing the inflammation in chronic pancreatitis.

The fact that no single approach is used for chronic Crohn's disease indicates the inadequacy of the various treatments.

Chronic ulcerative colitis can require proctocolectomy.

Summary of the Invention

It is an object of the invention herein to employ enteral nutrition to reverse established injury in inflammatory liver, pancreatic and intestinal disorders including alcoholic hepatitis, viral hepatitis, chronic pancreatitis, Crohn's disease and ulcerative colitis, and particularly to administer an enteral fat-containing diet which is low in polyunsaturated fats and preferably which is high in saturated fats.

The present invention is directed to a method of treating a patient having an inflammatory liver, pancreatic or intestinal disorder including, e.g., alcoholic hepatitis, chronic viral hepatitis, chronic pancreatitis, chronic Crohn's disease and chronic ulcerative colitis, said method consisting essentially of administering an enteral diet containing fat in an amount so the fat provides from 20 to 50 % of total calories, preferably from 30 to 40 % of total calories, said fat containing less than 15 % by weight polyunsaturated fat (total fatty acid source basis), preferably less than 10 % by weight of polyunsaturated fat (total fatty acid source basis), preferably containing at least 45 % by weight saturated fat (total fatty acid source basis), more preferably containing at least 50 % by weight saturated fat (total fatty acid source basis).

Detailed Description

As indicated by the term "enteral nutrition", administration herein is carried out enterally

that is into the gastrointestinal tract by mouth (orally) or through a naso-gastric tube or by other modes.

The diet administered may be that normally associated with enteral nutrition for liver, pancreatic and intestinal disorders except that the fat component is modified to meet the percentages recited above. Thus the diet is preferably an enteral emulsion consisting essentially of from 25 to 75 grams per liter of source of said fat and preferably also contains from 100 to 400 grams per liter of carbohydrate, e.g., from dextrose, sucrose, lactose, maltodextrin, corn syrup, glucose oligosaccharides, hydrolyzed cereal solids, tapioca starch, modified cornstarch, hydrolyzed cornstarch, or pureed fruits and vegetables, from 15 to 75 grams per liter of amino acids and protein, e.g., from free L-amino acids including free essential amino acids, caseinates, hydrolyzed whey, hydrolyzed casein, hydrolyzed lactalbumin, meat protein and soy protein, and vitamins and minerals, e.g., Vitamin A, B₁, B₂, B₃, B₅, B₆, B₁₂, C, D, E, K, biotin, choline, folic acid, Ca, Cl, Cr, Cu, Fe, I, Mg, Mn, Mo, P, Se, and Zn. These emulsions contain, for example, 1 to 2 kcal/ml.

The enteral diet is administered, for example, to provide an average of 25 ml/hr. to 125 ml/hr. and an average of 500 to 3000 kcal/day.

We turn now to the fat constituent of the enteral diet which is a novel feature for the method herein. As indicated above, the enteral diet contains fat in an amount so the fat provides from 20 to 50 % of total calories, preferably from 30 to 40 % of total calories, said fat containing

less than 15 % by weight polyunsaturated fat (total fatty acid source basis), preferably less than 10 % by weight of polyunsaturated fat (total fatty acid source basis), preferably containing at least 45 % by weight saturated fat (total fatty acid source basis), more preferably containing at least 50 % by weight saturated fat (total fatty acid source basis). The phrase "total fatty acid source basis" means that all the fatty acids in the diet are considered whether in the form of triglycerides, diglycerides, monoglycerides, free fatty acids, lecithin, or in other forms. The invention herein contemplates and includes use of compositions where saturated fatty acids constitute all the fatty acids on a total fatty acid source basis. Suitable fats which maybe used as the sole fat constituent to meet the requirement herein of no more than 15 % by weight of polyunsaturated fat (total fatty acid source basis) include butter fat, cocoa butter, coconut oil, lard, medium chain triglycerides (i.e., triglycerides which mainly contain C₈ and C₁₀ fatty acids, i.e., caprylic acid and capric acid), palm oil, palm kernal oil and tallow. These may be used in admixture with fats or other sources of fatty acids which alone do not meet said requirement when the admixture meets said requirement. Suitable fats also include those which are hydrogenated to meet said requirement.

The invention is illustrated in the following examples.

In the examples, an intragastric feeding rat model for alcoholic injury is used. This rat model is described in Tsukamoto, H., et al, Hapatology, 6, No. 5, 814-822 (1986); in French,

S. W., et al, Alcohol Clin. Exp. Res. 10:13S-19S (1986); and in Tsukamoto, H., et al, Hepatology, 12, 599-608 (1990). In accordance with this rat model, rats are fed a diet containing menhaden fish oil and ethanol for 6 weeks to induce alcohol-related liver injury. The amount of ethanol was initially 8 g/kg/day and was increased up to 16 g/kg/day as tolerance developed. The amount of menhaden fish oil was maintained at 35% of total calories. The diet also included protein (at about 25% of calories) and dextrose which together with the ethanol gave the remainder of the calories. Vitamins and minerals were also given as described in French et al and in Tsukamoto et al. In comparison to humans, the rats at the end of the 6-week period represent the equivalent of patients admitted to the hospital with alcohol related liver disease whereupon alcohol consumption ceases and nutritional support begins.

In Examples I and II, the protein consisted of casein hydrolysate.

Example I

Fifteen male Wistar rats (225-250g) were fed ethanol and menhaden fish oil for a six-week period in accordance with the intragastric feeding rat model for alcoholic injury described above. These were divided into three groups, each containing 5 of the rats.

At the end of the six-week period, a control group of 5 of the rats was sacrificed and determinations were made as described below.

At the end of the six-week period, biopsies were carried out on the second and third groups of 5 rats each, to confirm the occurrence of liver

injury.

At the end of the six-week period, the second group of 5 rats was switched to a diet of menhaden fish oil (35% of total calories), protein (about 25% of total calories) and dextrose (remainder of total calories) for two weeks with vitamins and minerals continued as before. The menhaden fish oil was found by analysis to contain the following percentages of fatty acids (total fatty acid basis): 0.2% C12:0, 10.3% C14:0, 1.1% C15:0, 20.0% C16:0, 1.2% C17:0, 3.4% C18:0, 2.1% C20:0, 14.8% C16:1, 0.3% C17:1, 12.3% C18:1, 2.6% C20:1, 0.6% C22:1, 0.2% C24:1, 1.6% C16:2, 2.0% C18:2, 3.7% C18:3, 0.5% C20:2, 0.4% C20:3, 0.7% C20:4, 9.8% C20:5, 1.8% C22:5, 6.1% C22:6 and 1.6% unknown and C19:1 alcohol, providing totals of 38.3% saturated fatty acid and 26.6% polyunsaturated fatty acid. At the end of the two-week period, the five rats of this group were sacrificed and determinations were made as described below.

At the end of the six-week period, the third group of 5 rats was switched to a diet of palm oil (35% of total calories), protein (about 25% of total calories) and dextrose (the remainder of total calories) for two weeks, with vitamins and minerals continued as before. The palm oil was found by analysis to contain the following percentages of fatty acids (total fatty acid basis): 0.4% C12:0, 1.2% C14:0, 44.8% C16:0, 3.9% C18:0, 50.0% C18:1n-9, 8.4% C18:2n-6 and 0.3% C20:0, providing totals of 50.6% saturated fatty acid and 8.4% polyunsaturated fatty acid. At the end of the two-week period, the five rats of this group were sacrificed and determinations were made

as described below.

Upon sacrifice, the livers of each group of rats were sectioned, formalin-fixed, hematoxylin and eosin stained for light microscopy and evaluated for inflammatory cells per mm^2 , foci of necrosis per mm^2 , and degree of fatty liver (scale of 1-4). In addition, evaluation for conjugated dienes was carried out by obtaining lipid extract of liver homogenate and measuring the optical density at 232 nm according to the method described in Recknagel, R.O, et al, Meth. Enzymol, 105:331-337 (1984).

For the control group, the following results were obtained: Fatty liver, 4.0 ± 0.0 ; necrosis, 1.2 ± 0.5 foci/ mm^2 ; inflammation, 27.3 ± 7.1 cells/ mm^2 ; conjugated dienes, 0.59 ± 0.30 .

For the second group of rats, the following results were obtained: Fatty liver, 2.8 ± 0.8 ; necrosis, 0.8 ± 0.6 foci/ mm^2 ; inflammation, 17.3 ± 7.8 cells/ mm^2 ; conjugated dienes, 0.33 ± 0.6 .

For the third group of rats, the following results were obtained: Fatty liver, 0.8 ± 0.7 ; necrosis, 0.2 ± 0.1 foci/ mm^2 ; inflammation, 2.0 ± 1.0 cells/ mm^2 ; conjugated dienes, 0.14 ± 0.01 .

The results for the group of rats fed palm oil were significantly better ($p < 0.01$) than the results for the other groups.

A comparison of liver fatty acid composition in the groups for rats fed palm oil/protein/dextrose versus menhaden fish oil/dextrose showed significantly higher levels of 18:2 n-6 (10.8 ± 0.7 vs. 4.2 ± 0.5) and 18:1 n-9 (15.9 ± 0.8 vs. 9.7 ± 1.2) and significantly lower levels of 20:5 n-3 (8.8 ± 1.8 vs. 14.2 ± 1.3) and 22:6 n-3 (10.8 ± 2.9 vs. 15.2 ± 0.4) in rats fed

palm oil/protein/dextrose.

Liver levels of alpha and gamma tocopherols were similar in all groups.

The results show that feeding palm oil to rats having established alcoholic liver disease caused a significant reduction in degree of fatty liver, necrosis and inflammation whereas feeding menhaden fish oil to rats having established alcoholic liver disease led to minimal improvement in liver pathology.

Example II

An experiment similar to that of Example I was carried out with 10 rats where at the end of the six week period 5 rats constituted the control group and 5 rats were switched to medium chain triglycerides (35% of total calories), protein (about 25% of total calories) and dextrose (remainder of total calories) with vitamins and minerals continued as before for 2 weeks. The medium chain triglycerides contained only saturated fatty acids.

The results for the control group were similar to those for the control group of Example I.

For the group of rats fed medium chain triglycerides and dextrose, the following results were obtained: Fatty liver, 1.0 ± 0.6 ; necrosis, 0.2 ± 0.2 foci/mm²; inflammation, 1.9 ± 1.6 cells/mm².

The results show that feeding medium chain triglycerides to rats having established alcoholic liver disease led to significant reduction in degree of fatty liver, necrosis and inflammation.

Palm oil (used in Example I) normally contains some Vitamin E. Medium chain

triglycerides do not contain Vitamin E. This example shows that the same results as are obtained in Example I are obtained without Vitamin E being present.

Example III

A patient with alcoholic hepatitis is admitted to a hospital. Liver biopsy shows fatty liver of about 4.0 ± 0.0 , necrosis of about 15.8 ± 1.9 foci/mm² and inflammation of about 100.2 ± 10.9 cells/mm².

Diet is administered orally consisting of enteral emulsion containing 45 g/L L-amino acids, 170 g/L maltodextrin/sucrose and 35 g/L palm oil or medium chain triglycerides at the rate of 600 ml/day.

At the end of 6 weeks, liver biopsy shows significantly improved liver pathologies.

Variations in the invention will be obvious to those skilled in the art. Thus, the invention is defined by the claims.

WHAT IS CLAIMED IS:

1. A method of treating a patient having an inflammatory liver, pancreatic or intestinal disorder, said method consisting essentially of administering an enteral diet containing fat in an amount so the fat provides from 20 to 50% of total calories, said fat containing less than 15% polyunsaturated fatty acids on a total fatty acid source basis, thereby to mediate amelioration of the inflammation associated with said disorder.

2. The method of claim 1 wherein the inflammatory disorder is alcoholic hepatitis and the treatment mediates healing of the liver.

3. The method of claim 1 wherein the method comprises administering an enteral diet containing fat so the fat provides from 30 to 40% of total calories, said fat containing less than 10% polyunsaturated fatty acids on a total fatty acid source basis and more than 45% saturated fatty acids on a total fatty acid source basis.

4. The method of claim 3 wherein the fat consists of palm oil.

5. The method of claim 3 wherein the fat consists of medium chain triglycerides.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/10141

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 37/02, 37/00

US CL : 514/552, 514/558, 514/893, 514/938, 514/943

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/552, 514/558, 514/893, 514/938, 514/943

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN CAS file MEDLINE, file BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 4,810,726 (BISTRAN ET AL) 07 MARCH 1989, SEE ENTIRE DOCUMENT.	1-5
X	CHEMICAL ABSTRACTS, VOLUME 70 ISSUED 1968, OJI ET AL. "ABNORMALITY OF PLASMA FATTY ACID COMPOSITION IN CHRONIC LIVER DISEASES AND ITS TREATMENT", NORA IGAKU ZASSHI (1968)(1914), 576-89, SEE ENTIRE DOCUMENT.	1-5



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, each combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

08 NOVEMBER 1995

Date of mailing of the international search report

28 NOV 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PAUL J. KILLOS jd

Telephone No. (703) 308-1235